News coverage about Minerva Neurosciences (NASDAQ:NERV) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Minerva Neurosciences earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 47.1368956705505 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
- Minerva Neurosciences, Inc.: Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director (finanznachrichten.de)
- BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman (reuters.com)
- Minerva Neurosciences (NERV) Downgraded to Strong Sell at ValuEngine (americanbankingnews.com)
- Head-To-Head Comparison: Minerva Neurosciences (NERV) & Its Peers (americanbankingnews.com)
NERV has been the subject of several research reports. BidaskClub upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. ValuEngine lowered shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $13.94.
Shares of Minerva Neurosciences (NASDAQ:NERV) traded up $0.10 during trading hours on Wednesday, reaching $5.70. 8,977 shares of the company traded hands, compared to its average volume of 256,212. Minerva Neurosciences has a one year low of $4.80 and a one year high of $11.15. The stock has a market capitalization of $222.53, a price-to-earnings ratio of -5.04 and a beta of 1.49.
In related news, CFO Geoff Race sold 5,829 shares of the company’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $5.79, for a total value of $33,749.91. Following the completion of the transaction, the chief financial officer now directly owns 197,698 shares in the company, valued at $1,144,671.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 12,590 shares of company stock valued at $73,073 over the last quarter. 21.60% of the stock is owned by company insiders.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.